

# TABLE OF CONTENTS

11

## CHAPTER 1

The in-betweeners: a short introduction

19

## CHAPTER 2

Clinical experience with  $\alpha$ -galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

45

## CHAPTER 3

Exploiting the CD1d-iNKT cell axis for potentiation of DC based cancer vaccines

61

## CHAPTER 4

Circulating Invariant Natural Killer T-Cell Numbers Predict Outcome in Head and Neck Squamous Cell Carcinoma: Updated Analysis With 10-Year Follow-Up

69

## CHAPTER 5

Activated iNKT cells promote  $V\gamma 9V\delta 2$ -T cell anti-tumor effector functions through the production of  $TNF-\alpha$ .

85

## CHAPTER 6

CD1d restricted Ag presentation by  $V\gamma 9V\delta 2$ -T cells requires trogocytosis

107

## CHAPTER 7

$V\gamma 9V\delta 2$ -T cells as antigen presenting cells for iNKT cell based cancer immunotherapy

# TABLE OF CONTENTS

<b>CHAPTER 8</b> Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells	<b>113</b>
<b>CHAPTER 9</b> The effects of systemic treatment with aminobisphosphonates and statins on circulating V $\gamma$ 9V $\delta$ 2-T cells in patients with advanced cancer	<b>131</b>
<b>CHAPTER 10</b> Summarizing discussion and future perspectives	<b>149</b>
<b>CHAPTER 11</b> Nederlandse Samenvatting	<b>161</b>
Curriculum Vitae	<b>171</b>
List of Publications	<b>175</b>
Dankwoord	<b>181</b>